10-K: Cryoport Reports Strong 2025 Revenue Growth, Strategic Divestiture

Cryoport, Inc. reported a 12.4% increase in total revenue to $176.2 million for fiscal year 2025, driven by strong demand in life sciences services and products, alongside the strategic divestiture of its CRYOPDP business.

Summary

• Total revenue increased by $19.4 million, or 12.4%, to $176.2 million for the year ended December 31, 2025, compared to $156.8 million in 2024.
• Life Sciences Services revenue grew by 17.6% to $96.5 million, with revenue from commercial cell and gene therapies increasing by 23.9% to $29.9 million.
• Life Sciences Products revenue increased by 6.6% to $79.7 million, driven by demand from EMEA, APAC, and animal health customers.
• The company reported a net income of $78.3 million for 2025, a significant improvement from a net loss of $114.8 million in 2024, primarily due to a $117.0 million gain on the divestiture of the CRYOPDP business.
• Adjusted EBITDA from continuing operations improved from a negative $17.8 million in 2024 to a negative $5.8 million in 2025, attributed to gross margin expansion and cost reduction initiatives.
• Cryoport supported 760 clinical trials, including 86 in Phase III, as of December 31, 2025.
• The divestiture of the specialty courier CRYOPDP business to DHL was completed for $133.0 million, including the repayment of $77.2 million in intercompany loans.
• Key product launches included the Cryoport Express Cryogenic HV3 Shipping System and MVE's integrated Condition Monitoring Services.
• Cryoport became the first organization globally certified to ISO 21973:2020 for the transportation of cells for therapeutic use.
• A new Global Supply Chain Center commenced BioLogistics services in Paris, France, in November 2025, with BioServices expected in Q4 2026.
• Cash and cash equivalents significantly increased to $250.5 million as of December 31, 2025, from $34.1 million in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, primarily driven by the strategic divestiture and return to net income, coupled with solid revenue growth in core life sciences services and products. The improvement in adjusted EBITDA from continuing operations is also a strong indicator of operational progress.

Positives

• Total revenue increased by 12.4% to $176.2 million, demonstrating strong top-line growth.
• Life Sciences Services revenue grew by 17.6% to $96.5 million, indicating robust demand for core offerings.
• Revenue from commercial cell and gene therapies increased by 23.9% to $29.9 million, highlighting success in a high-growth market.
• Achieved a net income of $78.3 million in 2025, a substantial turnaround from a $114.8 million net loss in 2024.
• The divestiture of CRYOPDP generated $133.0 million in proceeds and a $117.0 million gain, strengthening the balance sheet and strategic focus.
• Adjusted EBITDA from continuing operations improved significantly from negative $17.8 million to negative $5.8 million, reflecting operational efficiency gains.
• Expanded support to 760 clinical trials, including 86 in Phase III, indicating continued market penetration.
• Obtained global ISO 21973:2020 certification, a critical standard for the cell and gene therapy supply chain, reinforcing quality and compliance.
• Opened a new Global Supply Chain Center in Paris, France, and announced plans for additional centers in Santa Ana, California, and Tampa, Florida, expanding global infrastructure.
• MVE's manufacturing facilities are the first cryogenic systems manufacturing facilities to be registered with the FDA, ensuring high product quality and regulatory adherence.
• Strong liquidity position with cash and cash equivalents of $250.5 million at year-end 2025.

Negatives

• Reported a loss from continuing operations of $33.969 million in 2025, indicating that core operations are not yet profitable.
• Adjusted EBITDA from continuing operations, while improved, remains negative at $5.8 million.
• One customer in the Life Sciences Services segment accounted for 10.2% of total revenue in 2025, posing a customer concentration risk.
• Foreign currency translation adjustments resulted in a negative impact of $15.464 million on cash and cash equivalents.
• The company still carries an accumulated deficit of $688.9 million as of December 31, 2025.
• Total indebtedness and other liabilities stood at $262.4 million as of December 31, 2025.

Risks

• Exposure to economic, political, and other risks in different countries, including foreign currency exchange rate fluctuations, tariffs, and trade restrictions, which could reduce sales or increase liabilities.
• Dependence on the availability of certain component products from third-party manufacturers, some of which are sole-sourced, potentially leading to delays or increased costs.
• Products and services may contain errors or defects, which could result in reputational damage, lost revenues, increased service costs, litigation, and product recalls, particularly in human reproductive medicine.
• Risk of liability in excess of current insurance coverage, especially for damage to high-value biological specimens, materials, and samples.
• Business operations, financial performance, and results could be materially adversely affected by pandemics, epidemics, or other public health crises.
• Difficulty increasing revenues if delays, difficulties, or unanticipated costs are experienced in establishing sales, marketing, and distribution capabilities.
• Inaccurate forecasts of customer demand could lead to excess or obsolete equipment and/or inventory, or an inability to meet demand, adversely affecting operating results.
• Disruption or loss to factories, facilities, or distribution systems due to factors outside of control (e.g., natural disasters, carrier error) could seriously harm operations and biological materials.
• Operating in a competitive industry, with potential loss of business to competitors offering comparable, superior, or less costly products and services.
• Failure of successfully developed products and/or services to achieve and maintain market acceptance could prevent profitability.
• Integration and operation of acquired businesses may disrupt operations, create additional expenses, and may not achieve anticipated benefits.
• Impairment of goodwill and other intangible assets could have a material non-cash adverse impact on results of operations (e.g., $54.6 million impairment in 2024).
• Reliance on critical information systems, including the Cryoportal software platform; failure could adversely impact reputation and future revenues, and require increased spending on data and system security.
• Cyberattacks, data incidents, and breaches in the security of information systems and networks could materially adversely impact business, financial condition, and results of operations.
• Success depends on the ability to obtain patent protection, preserve trade secrets, and operate without infringing the proprietary rights of others.
• Complying with numerous country-specific and international regulations (e.g., CDC, OSHA, DOT, IATA, ICAO, FDA, FCC, FAA, GDPR) can limit activities and increase operational costs.
• Dependence on business partners and unrelated third-party agents in foreign countries to complete the importation process and delivery, with potential for customer dissatisfaction or liability if they fail.
• Changes in trade policy, tariff, and import/export regulations may have a material adverse effect on business, financial condition, and results of operations.
• Historically incurred significant losses and may continue to incur losses in the future, potentially impairing the ability to raise additional capital.
• Indebtedness and liabilities could limit cash flow available for operations and expose the company to risks.
• The issuance of Series C Preferred Stock reduces the relative voting power of common stockholders, dilutes ownership, and may adversely affect the market price of common stock.
• Series C Preferred Stockholders may exercise influence over the company, including through board nomination rights.
• Obligations to the Series C Preferred Stockholders could limit the ability to obtain additional financing or increase borrowing costs.
• Certain existing stockholders own and have the right to acquire a substantial number of common shares, which may delay or prevent a change in control.
• Future sales of shares of common stock may depress the price of shares and be dilutive to existing stockholders.
• The company's stock price has been and will likely continue to be volatile.
• No dividends have been paid on common stock in the past and are not expected in the foreseeable future, limiting return on investment to stock price appreciation.
• Articles of Incorporation allow the board to issue blank check preferred stock, which could discourage, delay, or prevent a change of control.
• Provisions in bylaws and Nevada law might discourage, delay, or prevent a change of control or changes in management.
• Ability to grow and compete will be hampered if unable to retain key professionals or to identify, hire, and retain additional qualified professionals.
• If equity research analysts do not publish research or reports, or issue unfavorable commentary or downgrade common stock, the price could decline.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it invests in new supply chain initiatives, geographic expansion, and technology to support anticipated growth. Management believes that current cash and cash equivalents, short-term investments, and projected cash flows will satisfy operational and capital requirements for at least the next twelve months. MVE plans to introduce the MVE CryoVerse Ecosystem in 2026, and new Global Supply Chain Centers are scheduled to open in Santa Ana, California (late 2026) and Tampa, Florida (mid-2027). BioServices operations are expected to commence in Paris, France, in the fourth quarter of 2026. The global cell and gene therapy market is projected to grow at an estimated 34% CAGR through 2028, which the company believes positions it well for continued benefit.

Management Comments

• "We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (CGT) market."
• "The divestiture and strategic partnership with DHL are expected to enhance our ability to develop our business, particularly in the Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions, and to provide differentiated and high-value services aligned with our long-term growth strategy."
• "We continue to lead the way in providing advanced temperature-controlled supply chain solutions designed to support the development of cell and gene therapies and our future growth."
• "Management believes that, based on its current plans and assumptions, which include the repayment of the 2026 Convertible Senior Notes at maturity, the current cash and cash equivalents on hand, short-term investments, together with projected cash flows, will satisfy our operational and capital requirements for at least the next twelve months."

Industry Context

StockSavvy.ai notes that Cryoport's strong revenue growth in Life Sciences Services, particularly in commercial cell and gene therapies, aligns with the broader industry trend of accelerated commercial expansion in the global CGT market, projected to grow at a 34% CAGR through 2028. The elimination of REMS requirements by the FDA in June 2025 for certain CAR-T therapies is a favorable regulatory development that should reduce logistical barriers and expand patient access, further supporting Cryoport's specialized supply chain solutions. The company's focus on end-to-end, digitally integrated solutions positions it well to capitalize on the increasing demand for standardized, scalable, and compliant supply chain services in this complex and highly regulated market.

Comparison to Industry Standards

• Cryoport's achievement of ISO 21973:2020 certification for cell therapy transportation is a significant industry benchmark, as it is the first standard specifically addressing the CGT supply chain, demonstrating leadership in specialized logistics.
• The company's support for 760 clinical trials and 20 commercially approved cell and gene therapies positions it as a leader in specialized logistics for advanced therapies, competing with global specialized couriers like World Courier (a Cencora company) and UPS Healthcare, but with a unique integrated platform approach.
• MVE Biological Solutions' FDA registration for its cryogenic systems manufacturing facilities sets a high standard for product quality and regulatory adherence in the cryogenic storage market, differentiating it from competitors such as Azenta Life Sciences and IC Biomedical.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not aware of any legal proceedings or claims that are believed to have, individually or in the aggregate, a material adverse effect on the business, operating results, or cash flows.

Related Party Transactions

• No disclosed related party dealings that are material in the context of specific transactions, although Series C Preferred Stockholders (Blackstone) have certain voting rights, conversion rights, and board nomination rights, which allow them to exercise influence over the company.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue, return to net income, and strategic divestiture. Potential for future dilution from equity issuances and stock price volatility.
• Employees: Anticipated hiring of additional personnel for global growth. Cost reduction initiatives mentioned in the Adjusted EBITDA explanation may have impacted headcount.
• Customers: Enhanced service offerings and global network expansion (Paris, Santa Ana, Tampa) are expected to better support cell and gene therapy programs.
• Suppliers: Dependence on third-party manufacturers for components introduces risks of delays or increased costs.
• Creditors: The company has $262.4 million in indebtedness and other liabilities, but management believes current liquidity is sufficient for the next 12 months.

Next Steps

• BioServices operations are expected to commence in the Paris Global Supply Chain Center in the fourth quarter of 2026.
• Another Global Supply Chain Center is scheduled to be opened in Santa Ana, California, in late 2026.
• CryoGene is scheduled to open its third biorepository in Tampa, FL, in mid-2027, primarily to support Moffitt Cancer Center.
• MVE plans to introduce the MVE CryoVerse Ecosystem, a proprietary connected platform, in 2026.
• MVE's expanded manufacturing line in Chengdu, China, is expected to commence cryogenic freezer production during the first quarter of 2026.
• The company expects to incur significant expenses and operating losses in the near term while making investments in new supply chain initiatives, geographic expansion, and technology.
• Additional personnel are anticipated to be hired to support the global growth strategy.

Key Dates

Recommendation

Cryoport's 2025 results demonstrate a strong strategic pivot and significant financial improvement, highlighted by a return to net income and substantial cash flow from the CRYOPDP divestiture. The core Life Sciences Services segment shows robust growth, particularly in the high-growth cell and gene therapy market, which is projected for continued expansion. While operating losses persist in continuing operations, the marked improvement in Adjusted EBITDA indicates effective cost management and a clear path towards sustainable profitability. The company's ongoing investments in global infrastructure, technology, and specialized services, coupled with key certifications and strategic partnerships, reinforce its leadership position in a critical and expanding industry. These factors suggest a positive long-term outlook for investors.

Keywords

Cell and Gene Therapy, Temperature-Controlled Supply Chain, BioLogistics, BioStorage, Cryopreservation, Cryogenic Systems, Life Sciences, Biopharmaceutical, Pharmaceutical, Healthcare Logistics, SEC Filing, 10-K, Cryoport, CYRX